6606.HK
New Horizon Health Limited [6606.HK] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
6606.HK Stock Summary
In the News
6606.HK Financial details
Company Rating
Buy
Market Cap
6.45B
Income
111.7M
Revenue
1.36B
Book val./share
6.18
Cash/share
3.47
Dividend
-
Dividend %
-
Employees
1.04K
Optionable
No
Shortable
Yes
Earnings
04 Mar 2024
P/E
-107.61
Forward P/E
-
PEG
10.48
P/S
12.18
P/B
4.07
P/C
4.07
P/FCF
-19.98
Quick Ratio
5.89
Current Ratio
8.8
Debt / Equity
0.15
LT Debt / Equity
0.14
-
-
EPS (TTM)
0.22
EPS next Y
-
EPS next Q
-
EPS this Y
-97.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-18.85%
Revenue last 5Y
109.81%
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-15%
SMA50
-22.73%
SMA100
-10.53%
Inst Own
-
Inst Trans
-
ROA
-3%
ROE
-4%
ROC
-0.02%
Gross Margin
84%
Oper. Margin
-7%
Profit Margin
-10%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
13.76-32.55
52W High
-55.81%
52W Low
+8.77%
RSI
25
Rel Volume
4.36
Avg Volume
1.22M
Volume
5.34M
Perf Week
-22.65%
Perf Month
-25.97%
Perf Quarter
-
Perf Half Y
-31.69%
-
-
-
-
Beta
1.302
-
-
Volatility
2.05%, 1.89%
Prev Close
0%
Price
14.14
Change
-19.66%
6606.HK Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.05 | 0.14 | 0.17 | 0.56 | 1.83 | |
| Net income per share | -0.54 | -0.25 | -1.89 | -8.21 | -0.19 | |
| Operating cash flow per share | -0.13 | -0.18 | -0.32 | -0.94 | -0.99 | |
| Free cash flow per share | -0.17 | -0.27 | -0.37 | -1.03 | -1.12 | |
| Cash per share | 0.18 | 0.83 | 1.39 | 4.6 | 3.21 | |
| Book value per share | -0.64 | -0.87 | -2.61 | 5.62 | 5.09 | |
| Tangible book value per share | -0.65 | -0.92 | -2.66 | 5.57 | 5.03 | |
| Share holders equity per share | -0.64 | -0.87 | -2.61 | 5.62 | 5.09 | |
| Interest debt per share | 0.03 | 0.2 | 0.38 | 0.35 | 0.61 | |
| Market cap | 30.81B | 31.35B | 29.54B | 6.83B | 6.48B | |
| Enterprise value | 30.74B | 31.08B | 29.24B | 6.26B | 5.6B | |
| P/E ratio | -137 | -294.44 | -37.46 | -2.2 | -80.71 | |
| Price to sales ratio | 1.64K | 537.93 | 418.66 | 32.09 | 8.47 | |
| POCF ratio | -551.84 | -418.04 | -223.3 | -19.25 | -15.71 | |
| PFCF ratio | -421.24 | -280.48 | -188.95 | -17.43 | -13.9 | |
| P/B Ratio | -114.32 | -85.75 | -27.11 | 3.21 | 3.06 | |
| PTB ratio | -114.32 | -85.75 | -27.11 | 3.21 | 3.06 | |
| EV to sales | 1.63K | 533.41 | 414.37 | 29.44 | 7.31 | |
| Enterprise value over EBITDA | -144.64 | -348.28 | -38.96 | -2.06 | -200.55 | |
| EV to operating cash flow | -550.68 | -414.52 | -221.02 | -17.66 | -13.56 | |
| EV to free cash flow | -420.35 | -278.12 | -187.01 | -15.99 | -12 | |
| Earnings yield | -0.01 | 0 | -0.03 | -0.45 | -0.01 | |
| Free cash flow yield | 0 | 0 | -0.01 | -0.06 | -0.07 | |
| Debt to equity | -0.04 | -0.23 | -0.14 | 0.06 | 0.12 | |
| Debt to assets | 0.04 | 0.15 | 0.18 | 0.05 | 0.1 | |
| Net debt to EBITDA | 0.3 | 2.95 | 0.4 | 0.19 | 31.77 | |
| Current ratio | 0.9 | 4.63 | 4.47 | 10.65 | 8.8 | |
| Interest coverage | -180.39 | -82.04 | -98.96 | -394.98 | -7.37 | |
| Income quality | 0.25 | 0.71 | 0.17 | 0.11 | 5.18 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0 | -1.88 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.74 | 0.25 | 1.47 | 0.6 | 0.21 | |
| Research and developement to revenue | 0.79 | 0.45 | 0.36 | 0.28 | 0.12 | |
| Intangibles to total assets | 0.01 | 0.03 | 0.02 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.31 | 0.49 | 0.18 | 0.1 | 0.13 | |
| Capex to revenue | -0.92 | -0.63 | -0.34 | -0.17 | -0.07 | |
| Capex to depreciation | -1.45 | -2.75 | -1.62 | -1.92 | -2.05 | |
| Stock based compensation to revenue | 0.23 | 0.18 | 0.21 | 0.11 | 0.09 | |
| Graham number | 2.79 | 2.24 | 10.52 | 32.21 | 4.7 | |
| ROIC | 0.12 | 0.41 | 0.84 | -1.35 | -0.02 | |
| Return on tangible assets | -0.75 | -0.2 | -0.99 | -1.33 | -0.03 | |
| Graham Net | -1.18 | -1.31 | -3.11 | 4.29 | 3.21 | |
| Working capital | -28.2M | 358.52M | 542.93M | 1.87B | 1.77B | |
| Tangible asset value | -273.68M | -384.7M | -1.11B | 2.11B | 2.1B | |
| Net current asset value | -327.94M | -454.7M | -1.21B | 1.83B | 1.55B | |
| Invested capital | -0.04 | -0.23 | -0.14 | 0.06 | 0.12 | |
| Average receivables | 0 | 8.94M | 25.15M | 69.21M | 330.02M | |
| Average payables | 0 | 39.81M | 14.49M | 24.51M | 73.65M | |
| Average inventory | 0 | 4.63M | 5.42M | 32.55M | 64.75M | |
| Days sales outstanding | 0 | 112.02 | 167.68 | 181.84 | 264.36 | |
| Days payables outstanding | 1.49K | 284.16 | 113.23 | 242.93 | 333.78 | |
| Days of inventory on hand | 110.43 | 71.9 | 67.15 | 370.33 | 216.73 | |
| Receivables turnover | 0 | 3.26 | 2.18 | 2.01 | 1.38 | |
| Payables turnover | 0.25 | 1.28 | 3.22 | 1.5 | 1.09 | |
| Inventory turnover | 3.31 | 5.08 | 5.44 | 0.99 | 1.68 | |
| ROE | 0.83 | 0.29 | 0.72 | -1.46 | -0.04 | |
| Capex per share | -0.04 | -0.09 | -0.06 | -0.1 | -0.13 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.27 | 0.78 | 0.78 | 0.85 | 0.85 | |
| Net income per share | -0.08 | -0.02 | -0.02 | 0.13 | 0.13 | |
| Operating cash flow per share | -0.28 | -0.25 | -0.25 | -0.36 | -0.36 | |
| Free cash flow per share | -0.3 | -0.3 | -0.3 | -0.43 | -0.43 | |
| Cash per share | 3.53 | 3.87 | 3.87 | 3.47 | 3.47 | |
| Book value per share | 4.92 | 6.12 | 6.12 | 6.18 | 6.18 | |
| Tangible book value per share | 4.86 | 6.1 | 6.06 | 6.13 | 6.13 | |
| Share holders equity per share | 4.92 | 6.12 | 6.12 | 6.18 | 6.18 | |
| Interest debt per share | 0.32 | 0.52 | 0.72 | 0.79 | 0.94 | |
| Market cap | 8.5B | 4.56B | 5.39B | 11.49B | 12.21B | |
| Enterprise value | 7.45B | 3.43B | 4.5B | 10.03B | 11.2B | |
| P/E ratio | -65.08 | -163.37 | -192.94 | 45.73 | 48.6 | |
| Price to sales ratio | 75.31 | 16.91 | 19.97 | 27.94 | 29.7 | |
| POCF ratio | -71.38 | -52.28 | -61.74 | -66.31 | -70.48 | |
| PFCF ratio | -66.81 | -44.34 | -52.37 | -54.85 | -58.29 | |
| P/B Ratio | 4.09 | 2.15 | 2.54 | 3.85 | 4.09 | |
| PTB ratio | 4.09 | 2.15 | 2.54 | 3.85 | 4.09 | |
| EV to sales | 66.03 | 12.71 | 16.68 | 24.39 | 27.24 | |
| Enterprise value over EBITDA | -138.65 | -106.18 | -139.33 | -550.07 | -614.23 | |
| EV to operating cash flow | -62.58 | -39.31 | -51.58 | -57.89 | -64.64 | |
| EV to free cash flow | -58.58 | -33.34 | -43.75 | -47.88 | -53.47 | |
| Earnings yield | 0 | 0 | 0 | 0.01 | 0.01 | |
| Free cash flow yield | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | |
| Debt to equity | 0.06 | 0.08 | 0.12 | 0.13 | 0.15 | |
| Debt to assets | 0.06 | 0.07 | 0.1 | 0.1 | 0.12 | |
| Net debt to EBITDA | 19.49 | 35.04 | 27.45 | 80 | 55.43 | |
| Current ratio | 9.23 | 8.8 | 8.8 | 10.77 | 10.77 | |
| Interest coverage | 0 | 0 | -7.51 | 0 | -4.18 | |
| Income quality | 3.65 | 12.5 | 12.5 | -2.76 | -2.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.26 | 0.19 | 0.19 | 0.16 | 0.16 | |
| Research and developement to revenue | 0.18 | 0.1 | 0.1 | 0.09 | 0.09 | |
| Intangibles to total assets | 0.01 | 0 | 0.01 | 0.01 | 0.01 | |
| Capex to operating cash flow | 0.07 | 0.18 | 0.18 | 0.21 | 0.21 | |
| Capex to revenue | -0.07 | -0.06 | -0.06 | -0.09 | -0.09 | |
| Capex to depreciation | -0.73 | -14.41 | -14.41 | -2.33 | -2.33 | |
| Stock based compensation to revenue | 0.05 | 0.11 | 0.11 | 0.08 | 0.08 | |
| Graham number | 2.93 | 1.67 | 1.67 | 4.25 | 4.25 | |
| ROIC | -0.03 | -0.01 | -0.01 | 0.07 | 0.07 | |
| Return on tangible assets | -0.01 | 0 | 0 | 0.02 | 0.02 | |
| Graham Net | 3.49 | 3.86 | 3.86 | 3.61 | 3.61 | |
| Working capital | 1.76B | 1.77B | 1.77B | 2.59B | 2.59B | |
| Tangible asset value | 2.05B | 2.11B | 2.1B | 2.96B | 2.96B | |
| Net current asset value | 1.72B | 1.55B | 1.55B | 2.17B | 2.17B | |
| Invested capital | 0.06 | 0.08 | 0.12 | 0.13 | 0.15 | |
| Average receivables | 0 | 413.02M | 554.05M | 760.33M | 966.61M | |
| Average payables | 0 | 52.24M | 75.79M | 81.86M | 79.7M | |
| Average inventory | 0 | 71.04M | 70.54M | 70.55M | 70.56M | |
| Days sales outstanding | 216.97 | 184.92 | 184.92 | 211.49 | 211.49 | |
| Days payables outstanding | 273.01 | 98.85 | 249.96 | 131.92 | 249.78 | |
| Days of inventory on hand | 317.48 | 162.31 | 162.31 | 168.96 | 168.96 | |
| Receivables turnover | 0.41 | 0.49 | 0.49 | 0.43 | 0.43 | |
| Payables turnover | 0.33 | 0.91 | 0.36 | 0.68 | 0.36 | |
| Inventory turnover | 0.28 | 0.55 | 0.55 | 0.53 | 0.53 | |
| ROE | -0.02 | 0 | 0 | 0.02 | 0.02 | |
| Capex per share | -0.02 | -0.05 | -0.05 | -0.07 | -0.07 |
6606.HK Frequently Asked Questions
What is New Horizon Health Limited stock symbol ?
New Horizon Health Limited is a CN stock and trading under the symbol 6606.HK
What is New Horizon Health Limited stock quote today ?
New Horizon Health Limited stock price is $14.14 today.
Is New Horizon Health Limited stock public?
Yes, New Horizon Health Limited is a publicly traded company.
Company Profile
- Volume Average 1.22M
- Market Capitalization 6.45B
- Employee 1.04K
- CEO Mr. Yeqing Zhu
- Headquarters Hangzhou,CN
- IPO Date 2021-02-18
-
Website
https://ir.newhorizonbio.com 
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.
